Further studies with HIF2α protein small molecule agonists should verify whether these molecules affect the cellular expression of IL-6 and reduce MIRI to provide a new target for the prevention and treatment of ischemic cardiomyopathy. This evidence concerns the gene IL6 and ischemic cardiomyopathy.